CA-ATLASSIAN
4.3.2014 17:04:42 CET | Business Wire | Pressemeddelelse
Comalatech, today announced the launch of Canvas for Atlassian JIRA OnDemand, built with Atlassian's new Atlassian Connect development framework. Canvas for JIRA helps organizations comprehend complexity by visualizing issues, like software bugs, new features, tasks, or support requests, on interactive boards. On the boards, users can manipulate these issues in dozens of ways. Simply dragging an issue across the customizable rows and columns changes JIRA attributes like assignee, version, label or an organization's custom fields.
Comalatech has been building add-ons for Atlassian products since 2007 and is one of the highest grossing developers in the Atlassian Marketplace . Comalatech's comprehensive line of add-ons covers workflows, page publishing and tools for visualization for Atlassian's on-premises versions of Confluence and JIRA. With the release of Canvas for JIRA and Confluence OnDemand, Comalatech brings its Canvas products for visually organizing content through boards to Atlassian's SaaS collaboration and issue tracking products.
In October 2013, Comalatech introduced Canvas for Confluence OnDemand to help teams brainstorm and collaborate on content. It comes pre-loaded with boards for business and agile development teams, such as Project Retrospectives, Product Roadmaps, and SWOT analysis. Teams can also build a custom board to support a framework specific to their needs. That release helped Comalatech tap into a new market of over 10,000 teams using Atlassian's SaaS products. The choice to reinvent Canvas as an add-on for JIRA was natural. According to Roberto Dominguez, CEO and founder of Comalatech, "Users loved Canvas for Confluence - they simply pressured us into making a version for JIRA."
"Atlassian Connect is a game-changer. It opens the Atlassian Marketplace to developers for both on-premises and SaaS versions of JIRA and Confluence," says Dominguez. "Since Atlassian announced their OnDemand service we've been rethinking our portfolio with Connect in mind. By offering substantial freedoms in choice of technology stack, Connect makes it easy to deliver a seamless user experience for Atlassian JIRA and Confluence."
"We re-imagined our Ad hoc Canvas product in the context of Connect and OnDemand, and we are delighted with the outcome - we achieved the promises of security, stability and scalability. Remote interfaces are a fabulous way to partition functionality in today's cloud environments, and our initial concerns about the latency of connections have not been a worry."
Comalatech gives credit to Atlassian's Marketplace for easing commercialization. "In 2013 we migrated our existing product line to Marketplace. It removed a lot of sales friction, which helped us reduce costs and allowed us to focus on building products and services that make money. Sales for Canvas for Confluence continue to exceed our expectations, we have every reason to expect the same or better for Canvas for JIRA."
About Comalatech
A leading provider of Atlassian add-ons for the past seven years, Comalatech's award-winning suite of products continue to enhance the way hundreds of businesses across the world create and manage their Confluence and JIRA content. Comalatech's flagship product, Ad hoc Workflows, is best known for adding process and compliance controls into Confluence, Atlassian's collaborative intranet and document sharing platform. Their other headline product, the award-winning Ad hoc Canvas, allows users to visually build and organize Confluence content through boards.
Learn more at http://www.comalatech.com/
Contact:
Atlassian
Aaron Forman, 415-701-1110 ext. 4450
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum